COMMUNIQUÉS West-GlobeNewswire

Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation
16/03/2026
RESEARCH TRIANGLE PARK, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement with Cipla [...]
Nadia Care Raises $12 Million to Expand Community-Centered Maternal Care Model Across the U.S.
16/03/2026
Expansion in DC, Maryland, and Tennessee Markets on the Heels of Excellent Outcomes WASHINGTON, March 16, 2026 (GLOBE NEWSWIRE) -- Nadia Care, the maternal health company formerly known as Cayaba Care, announced a $12 [...]
Solve GNE Highlights New Research, Expands Funding Efforts, and Advances Toward a Phase I Clinical Trial for GNE Myopathy
16/03/2026
LOS ANGELES, March 16, 2026 (GLOBE NEWSWIRE) -- Solve GNE, a nonprofit foundation dedicated to accelerating treatments for GNE myopathy, has announced major progress across its research, fundraising, and regulatory [...]
Flyte Launches Florida Hops to Service Accelerating Demand
16/03/2026
Fleet Expansion Underway With Five Vision Jets Expected to Be Operating by Memorial Day Regional Aviation Platform Now Connects Entire East Coast Following Successful Soft Launch in Florida FORT MILL, S.C., March 16, [...]
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
16/03/2026
TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company [...]
Qolab Announces John Martinis Prize as Momentum Builds for Scalable Quantum Hardware
16/03/2026
Debuting at APS Global Physics Summit with Quantum Machines and IQCC, Alongside New Collaborations, Education Programs, and Hiring Expansion DENVER, March 16, 2026 (GLOBE NEWSWIRE) -- Qolab today announced the launch of [...]
Novonesis issues EUR 1.7 billion in bonds to refinance bridge facility
16/03/2026
COPENHAGEN, Denmark – March 16, 2026 . Novonesis has completed a EUR 1.7 billion bond issuance, with significant interest from a broad group of investors. The transaction was primarily undertaken to refinance the bridge [...]
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth
16/03/2026
• Extends the budget period for the ~$2M total NIH grant funding award for DARE-PTB1 through November 2026 • DARE-PTB1 targets preterm birth, for which there are no FDA-approved treatment options • Award reflects Daré's [...]
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
16/03/2026
Early clinical proof-of-concept for WEE1 inhibitor APR-1051 in the ongoing ACESOT-1051 trial with two partial responders at first scan in endometrial cancer patients with PPP2R1A mutation Clinical team strengthened with [...]
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026
16/03/2026
Recruitment for the rheumatoid arthritis (RA) sub-study of the SKYWAY basket trial is complete; Week 12 topline data now expected in Q3 2026 Recruitment for the psoriatic arthritis (PsA) and axial spondyloarthritis ( [...]
Heartflow Builds Evidence Base Across the Heart Disease Care Continuum, From Precision Risk Stratification to CT-Guided Intervention Planning
16/03/2026
Three presentations at ACC reinforce Heartflow’s AI-powered technology predicts MACE, drives superior lipid outcomes and results in cost-effective care First patient enrolled in p ioneering N AVIGATE - PCI Registry [...]
Herantis Pharma to present HER-096 Phase 1b data at International Conference on Alzheimer’s & Parkinson’s Diseases
16/03/2026
Espoo, Finland, March 16, 2026: Herantis Pharma Plc ("Herantis"), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, announces that its Chief Scientific [...]
George Medicines extends global commercialization of GMRx2 into Australia and New Zealand with Arrotex licensing agreement
16/03/2026
Arrotex gains exclusive rights in Australia and New Zealand to innovative single pill combination of three hypertension medicines, including two doses that are lower than those currently available in single pill [...]
Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01
16/03/2026
STAFFORD, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Cronos Group Inc. to Speak at the 38th Annual ROTH Conference
16/03/2026
TORONTO, March 16, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President [...]
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
16/03/2026
MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in heavily pretreated [...]
Sotera Health Appoints Kenneth D. Krause to the Board of Directors
16/03/2026
CLEVELAND, March 16, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company” or “Sotera Health”), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and [...]
CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
16/03/2026
- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - Grade 3 diarrhea [...]
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
16/03/2026
- Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results - - Topline results of the global Phase 2 [...]

Pages